NCT00742560 - A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Hematologic Cancer

Interventions

BIOLOGICAL

elotuzumab

Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.

DRUG

lenalidomide

Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle

DRUG

dexamethasone oral

Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)

DRUG

dexamethasone injection

Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)